Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

US FDA accepts Pfizer’s sNDA for Xeljanz to treat ulcerative colitis

pharmaceutical-technologyJuly 18, 2017

Tag: US FDA , Pfizer , ulcerative colitis

PharmaSources Customer Service